Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

(2022) Adam D. Cohen et al.   Blood Cancer Journal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T-cell therapy in multiple myeloma: more room for improvement

(2021) Phaik Ju Teoh et al.   Blood Cancer Journal

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

(2021) Tom Martin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

(2021) Sundar Jagannath et al.   Blood Cancer Journal

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

(2021) Yael C. Cohen et al.   BLOOD

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

(2021) Thomas Martin et al.   BLOOD

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa

(2021) Larry D. Anderson et al.   Clinical Lymphoma Myeloma & Leukemia

Development of CAR-T cell therapies for multiple myeloma

(2020) Nico Gagelmann et al.   LEUKEMIA

B-cell maturation antigen expression across hematologic cancers: a systematic literature review

(2020) Ahmet Dogan et al.   Blood Cancer Journal

CAR-T design: Elements and their synergistic function

(2020) Jayapriya Jayaraman et al.   EBioMedicine

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

(2020) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

(2020) Gils Roex et al.   Journal of Hematology & Oncology

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma

(2019) Paolo Strati et al.   Current Oncology Reports

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

(2019) Smita S. Chandran et al.   IMMUNOLOGICAL REVIEWS

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

(2019) Marijke Timmers et al.   Frontiers in Immunology

Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide

(2019) Melissa Works et al.   MOLECULAR CANCER THERAPEUTICS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

CARs and other T cell therapies for MM: The clinical experience

(2018) Sophia Danhof et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

(2018) Miliotou N. Androulla et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials

(2018) Naveen Mangal et al.   HEMATOLOGICAL ONCOLOGY

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

(2018) Noelle Frey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Adoptive cellular therapies: the current landscape

(2018) Maartje W. Rohaan et al.   VIRCHOWS ARCHIV

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy

(2015) Xiang-Jun Tang et al.   Oncotarget

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening

(2015) Douglas E. Wood   Thoracic Surgery Clinics

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors

(2014) Chuan Jin et al.   Molecular Therapy-Methods & Clinical Development

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

(2008) C. S. Hinrichs et al.   BLOOD